JP2020075926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020075926A5 JP2020075926A5 JP2020002597A JP2020002597A JP2020075926A5 JP 2020075926 A5 JP2020075926 A5 JP 2020075926A5 JP 2020002597 A JP2020002597 A JP 2020002597A JP 2020002597 A JP2020002597 A JP 2020002597A JP 2020075926 A5 JP2020075926 A5 JP 2020075926A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- complementarity determining
- determining regions
- chain complementarity
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462054167P | 2014-09-23 | 2014-09-23 | |
| US62/054,167 | 2014-09-23 | ||
| JP2017515768A JP6694877B2 (ja) | 2014-09-23 | 2015-09-22 | 抗ｉｌ−２５抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515768A Division JP6694877B2 (ja) | 2014-09-23 | 2015-09-22 | 抗ｉｌ−２５抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020075926A JP2020075926A (ja) | 2020-05-21 |
| JP2020075926A5 true JP2020075926A5 (https=) | 2020-07-27 |
| JP6916319B2 JP6916319B2 (ja) | 2021-08-11 |
Family
ID=54207847
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515768A Active JP6694877B2 (ja) | 2014-09-23 | 2015-09-22 | 抗ｉｌ−２５抗体およびその使用 |
| JP2020002597A Active JP6916319B2 (ja) | 2014-09-23 | 2020-01-10 | 抗ｉｌ−２５抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515768A Active JP6694877B2 (ja) | 2014-09-23 | 2015-09-22 | 抗ｉｌ−２５抗体およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9840557B2 (https=) |
| EP (1) | EP3197914B1 (https=) |
| JP (2) | JP6694877B2 (https=) |
| KR (1) | KR102576368B1 (https=) |
| CN (1) | CN107207589B (https=) |
| AU (1) | AU2015321517B2 (https=) |
| CA (1) | CA2961517C (https=) |
| CL (2) | CL2017000703A1 (https=) |
| CO (1) | CO2017003072A2 (https=) |
| EA (1) | EA036658B1 (https=) |
| IL (1) | IL251001B (https=) |
| MA (1) | MA40106A1 (https=) |
| MX (1) | MX2017003841A (https=) |
| MY (1) | MY185832A (https=) |
| PH (1) | PH12017500403A1 (https=) |
| SG (2) | SG11201701712WA (https=) |
| WO (1) | WO2016049000A2 (https=) |
| ZA (1) | ZA201701663B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840557B2 (en) | 2014-09-23 | 2017-12-12 | Regeneron Pharmaceuticals, Inc. | Anti-IL-25 antibodies and uses thereof |
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
| CN107213463A (zh) * | 2017-05-24 | 2017-09-29 | 清华大学 | 白介素25在银屑病的发育中的作用 |
| DE102017215154A1 (de) | 2017-08-30 | 2019-02-28 | Markus Bläss | Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen |
| KR102598319B1 (ko) * | 2018-11-19 | 2023-11-02 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항-il-25 항체 및 그의 용도 |
| WO2021127500A1 (en) | 2019-12-20 | 2021-06-24 | Momenta Pharmaceuticals, Inc. | Antibodies against integrin alpha 11 beta 1 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
| WO2022150660A1 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| US20240400671A1 (en) * | 2021-10-05 | 2024-12-05 | Richard A. Shimkets | Monoconal antibodies to il-25 and uses thereof |
| AU2023223413A1 (en) * | 2022-02-24 | 2024-10-10 | Sinomab Bioscience Limited | Bispecific binding proteins against alarmins and uses thereof |
| EP4511634A4 (en) * | 2022-04-18 | 2026-03-25 | Access Medical Systems Ltd | ENZYMATIC AMPLIFICATION HIGH SENSITIVITY BIOLAYER INTERFEROMETRY |
| JP2026513302A (ja) * | 2023-03-31 | 2026-04-23 | ノヴァロック バイオセラピューティクス， リミテッド | 抗ｉｌ－２５抗体及びその使用方法 |
| WO2026067830A1 (zh) * | 2024-09-30 | 2026-04-02 | 深圳市小分子新药创新中心有限公司 | 抗il-25单域抗体及其衍生物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| GB0707505D0 (en) | 2007-04-18 | 2007-05-30 | Medical Res Council | Antibodies against il-25 |
| GB0817891D0 (en) * | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| HUE036157T2 (hu) | 2010-03-30 | 2018-06-28 | Janssen Biotech Inc | Humanizált IL-25 ellenanyagok |
| WO2012097126A2 (en) * | 2011-01-13 | 2012-07-19 | The University Of Maryland, Baltimore | Il-25 treatment of obesity and metabolic disorders |
| JP2015521591A (ja) * | 2012-06-12 | 2015-07-30 | オレガ・バイオテック | Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用 |
| US9840557B2 (en) | 2014-09-23 | 2017-12-12 | Regeneron Pharmaceuticals, Inc. | Anti-IL-25 antibodies and uses thereof |
-
2015
- 2015-09-22 US US14/861,320 patent/US9840557B2/en active Active
- 2015-09-22 MA MA40106A patent/MA40106A1/fr unknown
- 2015-09-22 EA EA201790441A patent/EA036658B1/ru unknown
- 2015-09-22 CN CN201580063385.9A patent/CN107207589B/zh active Active
- 2015-09-22 MY MYPI2017700743A patent/MY185832A/en unknown
- 2015-09-22 EP EP15771489.0A patent/EP3197914B1/en active Active
- 2015-09-22 MX MX2017003841A patent/MX2017003841A/es unknown
- 2015-09-22 SG SG11201701712WA patent/SG11201701712WA/en unknown
- 2015-09-22 KR KR1020177009048A patent/KR102576368B1/ko active Active
- 2015-09-22 WO PCT/US2015/051407 patent/WO2016049000A2/en not_active Ceased
- 2015-09-22 AU AU2015321517A patent/AU2015321517B2/en active Active
- 2015-09-22 CA CA2961517A patent/CA2961517C/en active Active
- 2015-09-22 JP JP2017515768A patent/JP6694877B2/ja active Active
- 2015-09-22 SG SG10201913084PA patent/SG10201913084PA/en unknown
-
2017
- 2017-03-03 PH PH12017500403A patent/PH12017500403A1/en unknown
- 2017-03-07 IL IL251001A patent/IL251001B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01663A patent/ZA201701663B/en unknown
- 2017-03-23 CL CL2017000703A patent/CL2017000703A1/es unknown
- 2017-03-29 CO CONC2017/0003072A patent/CO2017003072A2/es unknown
- 2017-11-07 US US15/805,584 patent/US10640558B2/en active Active
-
2018
- 2018-12-14 CL CL2018003608A patent/CL2018003608A1/es unknown
-
2020
- 2020-01-10 JP JP2020002597A patent/JP6916319B2/ja active Active
- 2020-02-27 US US16/803,582 patent/US11542326B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020075926A5 (https=) | ||
| US12600771B2 (en) | Antibody for binding to interleukin 4 receptor | |
| JP2014237671A5 (https=) | ||
| Nirula et al. | Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases | |
| AU2008334605B2 (en) | Polypeptides, antibody variable domains & antagonists | |
| JP2019531273A5 (https=) | ||
| JP7434456B2 (ja) | 抗ｉｌ－１３抗体を使用する、ｉｌ－１３活性が有害である疾患の治療方法 | |
| RU2640025C2 (ru) | Способы и композиции для лечения астмы с использованием антител против il-13 | |
| JP2017079785A5 (https=) | ||
| Heck et al. | Pharmacological therapy of bronchial asthma: the role of biologicals | |
| JP2017533888A5 (https=) | ||
| CN102037011A (zh) | 用于治疗银屑病的方法 | |
| JP2016536327A5 (https=) | ||
| Molinelli et al. | Biologic therapy in immune mediated inflammatory disease: basic science and clinical concepts | |
| JP2025122028A (ja) | Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 | |
| JP2010515774A (ja) | 乾せんの治療方法 | |
| JP2025164767A (ja) | Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 | |
| JP6663910B2 (ja) | 抗ＴＮＦ−α抗体療法を受けた乾癬患者を治療するための方法 | |
| Dandash et al. | Targeting the double-edged sword: cytokines in the pathogenesis and treatment of autoimmune diseases | |
| Imanirad et al. | Current biologics in asthma treatment | |
| de Oliveira et al. | Immunobiological therapy in the treatment of severe asthma | |
| NZ730105B2 (en) | Anti-il-25 antibodies and uses thereof | |
| NZ730105A (en) | Anti-il-25 antibodies and uses thereof | |
| HK1250166B (zh) | 用於结合白细胞介素4受体的抗体 | |
| TW202544036A (zh) | 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病 |